Papillary thyroid cancer is the most common form of thyroid cancer, accounting for about 80 to 85 percent of all thyroid cancer cases. Although hearing the word “cancer” can be frightening, this type of cancer typically grows slowly and responds very well to treatment, with survival rates approaching 100 percent for many patients, especially when diagnosed early.

How Doctors Approach Treatment for Papillary Thyroid Cancer

When someone receives a diagnosis of papillary thyroid cancer, the main goal of treatment is to remove the cancer completely, prevent it from coming back, and help the patient maintain a good quality of life. Treatment decisions depend on several important factors, including the size of the tumor, whether it has spread to nearby lymph nodes or other parts of the body, the patient’s age, and their overall health condition. In most cases, the cancer is found when it is still small and has not spread beyond the thyroid gland, which significantly improves the chances of successful treatment.

The approach to treating papillary thyroid cancer has evolved significantly over the past few decades. Medical societies and expert groups have developed detailed guidelines based on research and clinical experience. These guidelines help doctors decide which patients need more aggressive treatment and which ones can be managed with less invasive approaches. For very small, low-risk cancers, some patients may even be candidates for active surveillance, which means carefully monitoring the cancer with regular ultrasounds instead of rushing into surgery. This option recognizes that many small papillary thyroid cancers remain stable for years and may never cause problems.

Beyond the standard treatments that doctors have used for decades, researchers continue to study new therapies in clinical trials. These trials test innovative approaches that may offer hope to patients whose cancer is more advanced or does not respond to conventional treatments. The landscape of thyroid cancer treatment is constantly improving, with new medications and techniques emerging from ongoing research around the world.

Standard Treatment Approaches

Surgery as the Primary Treatment

Surgery remains the cornerstone of treatment for papillary thyroid cancer. The type of surgical procedure depends on the characteristics of the cancer. For smaller tumors that are confined to one side of the thyroid gland, doctors may perform a thyroid lobectomy, which means removing only one half of the butterfly-shaped thyroid gland. This procedure may be appropriate when the cancer is 1 to 4 centimeters in size, has not spread to lymph nodes, and the patient has never been exposed to radiation.

More commonly, patients undergo a total thyroidectomy, where the surgeon removes the entire thyroid gland. This approach is typically recommended for larger tumors, cancers that are present in both lobes of the thyroid, or cases where the cancer has already spread to lymph nodes. Removing the entire thyroid makes it easier to monitor for cancer recurrence later and allows for additional treatment with radioactive iodine if needed.

Up to 30 percent of patients have cancer that has spread to lymph nodes in the neck by the time of diagnosis. When this happens, the surgeon will also perform a neck dissection or lymphadenectomy, removing the affected lymph nodes and surrounding tissue. Unlike many other cancers, where lymph node involvement dramatically worsens the outlook, papillary thyroid cancer patients with lymph node spread still have excellent survival rates. The lymph nodes may increase the chance of the cancer returning, but they typically do not affect overall survival.

Surgery for thyroid cancer carries certain risks that patients should understand. The procedure involves working near important structures in the neck, including the nerves that control the vocal cords and the parathyroid glands, which are tiny organs that regulate calcium levels in the blood. Damage to the vocal cord nerves can cause hoarseness or voice changes, while injury to the parathyroid glands can lead to low calcium levels, requiring calcium supplements. These complications are less common when surgery is performed by experienced, high-volume thyroid surgeons who operate on many thyroid cancer patients each year.

Radioactive Iodine Therapy

After surgery, many patients receive radioactive iodine therapy, abbreviated as RAI. This treatment takes advantage of a unique property of thyroid cells: they naturally absorb iodine from the bloodstream. When a patient takes radioactive iodine, usually in the form of a pill or liquid, any remaining thyroid tissue or cancer cells absorb it. The radiation then destroys these cells from the inside.

Radioactive iodine therapy is particularly useful for eliminating any microscopic thyroid cancer cells that may have been left behind after surgery. It is often recommended when there is a risk that some cancer cells remain, when the tumor was large, or when cancer has spread to lymph nodes. The treatment can also target cancer that has spread to distant parts of the body, such as the lungs or bones, although distant spread is uncommon in papillary thyroid cancer.

Not all patients need radioactive iodine treatment. For very small, low-risk cancers that were completely removed during surgery, doctors may decide that RAI is unnecessary. The decision depends on careful assessment of the cancer’s characteristics and the completeness of the surgical removal. During RAI treatment, patients must follow special dietary restrictions to reduce the amount of regular, non-radioactive iodine in their body, which helps the radioactive form work more effectively.

Thyroid Hormone Replacement

After a total thyroidectomy, patients must take thyroid hormone medication for the rest of their lives. This medication, called levothyroxine, replaces the hormone that the thyroid gland would normally produce. Without this hormone, the body cannot maintain normal metabolism, energy levels, heart rate, and other essential functions. Even patients who have only one lobe removed may eventually need thyroid hormone replacement if the remaining lobe cannot produce enough hormone.

Thyroid hormone therapy serves two important purposes. First, it maintains normal body functions by providing the hormone the body needs. Second, in some cases, doctors prescribe slightly higher doses to suppress production of thyroid-stimulating hormone (TSH) from the pituitary gland. This approach, called thyroid hormone suppression therapy, can help prevent any remaining cancer cells from growing, because thyroid cancer cells often respond to TSH by multiplying. The appropriate dose of thyroid hormone varies for each patient and requires regular blood tests to monitor and adjust.

Taking thyroid hormone replacement as prescribed is crucial. When patients take the medication consistently and maintain appropriate thyroid hormone levels in their blood, they should not experience weight gain, fatigue, or hair loss that many people worry about. These symptoms typically occur only when thyroid levels are not properly controlled. Regular follow-up visits, usually every six months to a year, ensure that the medication dose remains correct.

External Beam Radiation Therapy

While less commonly used for papillary thyroid cancer, external beam radiation therapy involves directing high-energy X-rays at the cancer from outside the body. This approach may be considered in rare situations where the cancer is large and aggressive, has invaded surrounding tissues in the neck, cannot be completely removed by surgery, or does not respond to radioactive iodine. External radiation is more often used if there are signs that the cancer has returned after initial treatment and other options are limited.

Ongoing Monitoring and Follow-up Care

Treatment does not end when surgery and radioactive iodine therapy are complete. Lifelong monitoring is essential because papillary thyroid cancer can occasionally return, sometimes many years after initial treatment. Regular follow-up appointments typically include blood tests to measure thyroglobulin, a protein produced by thyroid cells. Since the thyroid has been removed, any detectable thyroglobulin suggests that thyroid cancer cells may still be present in the body.

Doctors also perform neck ultrasounds to visually examine the area where the thyroid was located and to check nearby lymph nodes for any signs of cancer recurrence. These ultrasounds are painless, involve no radiation exposure, and can detect very small abnormalities. In some cases, doctors may also order radioactive iodine uptake scans, which help identify any thyroid tissue or cancer cells that are absorbing iodine. If suspicious areas are found on ultrasound, a fine needle aspiration biopsy may be performed to determine whether cancer has returned.

Treatment in Clinical Trials: Exploring New Options

Clinical trials play a vital role in advancing treatment for papillary thyroid cancer, particularly for patients whose disease is more advanced or does not respond to standard treatments. These research studies test new medications, combinations of therapies, and innovative approaches that may eventually become standard care. Participating in a clinical trial gives patients access to cutting-edge treatments while contributing to medical knowledge that will help future patients.

Targeted Therapies and Molecular Treatments

One of the most exciting areas of research involves targeted therapies, medications that attack specific molecular abnormalities in cancer cells. Scientists have discovered that many thyroid cancers have mutations or changes in certain genes that drive the cancer’s growth. By developing drugs that specifically target these abnormalities, researchers hope to create more effective treatments with fewer side effects than traditional chemotherapy.

Several targeted therapies called tyrosine kinase inhibitors are being studied in clinical trials for papillary thyroid cancer. These drugs work by blocking enzymes called tyrosine kinases, which cancer cells use to grow and spread. Some of these medications have already been approved for advanced or metastatic thyroid cancer that no longer responds to radioactive iodine. Examples include drugs that target specific genetic changes found in thyroid cancer cells, such as mutations in the BRAF gene or alterations in other molecular pathways.

Researchers conduct clinical trials in different phases. Phase I trials primarily test the safety of a new drug and determine the appropriate dose. These early studies involve small numbers of patients and focus on understanding side effects. Phase II trials evaluate whether the drug is effective against the cancer, looking at outcomes like tumor shrinkage and slowing of cancer progression. Phase III trials compare the new treatment with the current standard treatment to determine if it offers better results.

Immunotherapy Approaches

Another promising area of research involves immunotherapy, treatments that harness the patient’s own immune system to fight cancer. The immune system normally identifies and destroys abnormal cells, but cancer cells often develop ways to hide from or suppress immune responses. Immunotherapy drugs help the immune system recognize and attack cancer cells more effectively.

Several types of immunotherapy are being investigated for thyroid cancer. Some drugs, called checkpoint inhibitors, block proteins that prevent immune cells from attacking cancer. By releasing these brakes on the immune system, the medications allow immune cells to mount a stronger response against the tumor. Other immunotherapy approaches include vaccines designed to train the immune system to recognize specific features of thyroid cancer cells, though these remain largely experimental.

Novel Drug Combinations and Treatment Strategies

Clinical trials are also exploring whether combining different types of treatments produces better results than using them alone. For example, researchers are studying whether pairing targeted therapy drugs with immunotherapy creates a more powerful effect against advanced thyroid cancer. Some trials investigate the optimal timing and sequencing of treatments to maximize effectiveness while minimizing side effects.

Preliminary results from some clinical trials have shown encouraging outcomes. In certain studies, patients with advanced papillary thyroid cancer that had stopped responding to radioactive iodine experienced tumor shrinkage or stabilization when treated with targeted therapy drugs. Other trials have demonstrated improved progression-free survival, meaning patients lived longer without their cancer worsening. While these results are promising, it is important to remember that clinical trials are research studies, and not all experimental treatments prove to be effective.

Where Clinical Trials Take Place and Who Can Participate

Clinical trials for papillary thyroid cancer are conducted at major medical centers and cancer research institutions throughout the world, including locations in the United States, Europe, and other regions. Many trials have specific eligibility requirements, which may include factors such as the stage of cancer, previous treatments received, genetic characteristics of the tumor, and the patient’s overall health status.

Patients interested in clinical trials should discuss this option with their healthcare team. Doctors can help determine whether a patient might be eligible for any available trials and explain the potential benefits and risks. Participation in a clinical trial is always voluntary, and patients can withdraw at any time. Many patients find that joining a trial provides hope and a sense of contributing to progress against cancer, even when they are facing a challenging diagnosis.

Most Common Treatment Methods

• Surgery
  • Thyroid lobectomy: removal of one lobe of the thyroid gland, appropriate for small, low-risk cancers confined to one side
  • Total thyroidectomy: removal of the entire thyroid gland, recommended for larger tumors or cancer in both lobes
  • Neck dissection (lymphadenectomy): removal of lymph nodes and surrounding tissue when cancer has spread to the neck
• Radioactive Iodine Therapy
  • Treatment taken orally as a pill or liquid that destroys remaining thyroid tissue and cancer cells
  • Particularly useful after surgery to eliminate microscopic cancer cells
  • Can target cancer that has spread to distant organs like lungs or bones
• Thyroid Hormone Replacement
  • Levothyroxine medication taken daily for life after thyroid removal
  • Replaces hormones the thyroid normally produces
  • May be given in higher doses to suppress cancer growth in some patients
• External Beam Radiation Therapy
  • High-energy X-rays directed at cancer from outside the body
  • Used rarely for aggressive cancers that invade surrounding tissues
  • May be considered when cancer does not respond to radioactive iodine or has recurred
• Targeted Therapy
  • Tyrosine kinase inhibitors that block specific enzymes cancer cells use to grow
  • Drugs targeting genetic mutations like BRAF or other molecular pathways
  • Used primarily for advanced cancer that no longer responds to radioactive iodine
• Immunotherapy
  • Checkpoint inhibitors that help the immune system recognize and attack cancer cells
  • Experimental vaccines designed to train immune system against thyroid cancer
  • Being studied in clinical trials, particularly for advanced disease
• Active Surveillance
  • Careful monitoring with regular ultrasounds for very small, low-risk cancers
  • Avoids surgery in select patients whose tumors remain stable
  • Requires strict criteria including small tumor size and no lymph node involvement